Glenmark launches Bumetanide injection continuing focus on institutional business

Glenmark Pharmaceuticals Inc has launched the Bumetanide injection, which is used in the treatment of fluid retention and swelling caused by congestive heart failure, liver disease, kidney disease, or other conditions.

The pharma major on Monday said that it has launched Bumetanide injection USP, (1 mg/4 ml) single-dose vials and 2.5 mg/10 ml multi-dose vials, the generic version of Bumex injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.

According to IQVIA sales data for the 12-month period ending in November 2022, the Bumex Injection 0.25 mg/mL market achieved annual sales of $16.5 million.